Literature DB >> 15390073

Comparison of diffusion-weighted imaging and [123I]IBZM-SPECT for the differentiation of patients with the Parkinson variant of multiple system atrophy from those with Parkinson's disease.

Klaus Seppi1, Michael F H Schocke, Eveline Donnemiller, Regina Esterhammer, Christian Kremser, Christoph Scherfler, Anja Diem, Werner Jaschke, Gregor K Wenning, Werner Poewe.   

Abstract

Both dopamine D2 receptor (D2R) binding single-photon emission computed tomography (SPECT) with [123I]iodobenzamide (IBZM) and diffusion-weighted imaging (DWI) have been shown to contribute to the differential diagnosis of patients with the Parkinson variant of multiple system atrophy (MSA-P) and Parkinson's disease (PD). We aimed to compare these two routinely available functional imaging modalities in differentiating patients with MSA-P from PD. For this purpose, results obtained by DWI and IBZM-SPECT were intraindividually compared in a cross-sectional study of 15 MSA-P and 17 PD patients matched for age and disease duration. The activity ratios of striatal to frontal cortex uptake (S/FC ratio) were used as a semiquantitative measure of the relative density of basal ganglia dopamine receptors labeled by IBZM. Regional apparent diffusion coefficients (rADC) were determined in the striatum. MSA-P patients had significantly lower S/FC ratios and significantly higher striatal rADCs than both PD patients and healthy volunteers. There were no significant differences in S/FC ratios and striatal rADC between PD patients and healthy volunteers. Sensitivity of IBZM-SPECT versus DWI for the differentiation of MSA-P from PD was 80% versus 93%, specificity 71% versus 100%, the predictive accuracy 75% versus 97%, the positive predictive value 71% versus 100%, and the negative predictive value 80% versus 94%. Striatal rADCs had a significant higher overall predictive accuracy than D2R binding with IBZM. In summary, our data suggest that DWI may be more accurate compared to IBZM-SPECT in the differential diagnosis of MSA-P versus PD. 2004 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15390073     DOI: 10.1002/mds.20229

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  20 in total

Review 1.  How to diagnose MSA early: the role of magnetic resonance imaging.

Authors:  K Seppi; M F H Schocke; G K Wenning; W Poewe
Journal:  J Neural Transm (Vienna)       Date:  2005-07-06       Impact factor: 3.575

Review 2.  Magnetic resonance imaging for the diagnosis of Parkinson's disease.

Authors:  Beatrice Heim; Florian Krismer; Roberto De Marzi; Klaus Seppi
Journal:  J Neural Transm (Vienna)       Date:  2017-04-04       Impact factor: 3.575

Review 3.  [Differential diagnosis of parkinsonian syndromes using MRI].

Authors:  P Mahlknecht; M Schocke; K Seppi
Journal:  Nervenarzt       Date:  2010-10       Impact factor: 1.214

4.  Examining the relationship between head trauma and neurodegenerative disease: A review of epidemiology, pathology and neuroimaging techniques.

Authors:  Mark H Sundman; Eric E Hall; Nan-Kuei Chen
Journal:  J Alzheimers Dis Parkinsonism       Date:  2014-01-31

Review 5.  Diagnosis of multiple system atrophy.

Authors:  Jose-Alberto Palma; Lucy Norcliffe-Kaufmann; Horacio Kaufmann
Journal:  Auton Neurosci       Date:  2017-10-23       Impact factor: 3.145

6.  T2*-weighted MRI in diagnosis of multiple system atrophy. A practical approach for clinicians.

Authors:  Friederike von Lewinski; Carola Werner; Torsten Jörn; Alexander Mohr; Friederike Sixel-Döring; Claudia Trenkwalder
Journal:  J Neurol       Date:  2007-03-14       Impact factor: 4.849

7.  Possible impact of dopamine SPECT on decision-making for drug treatment in Parkinsonian syndrome.

Authors:  S Hesse; C Oehlwein; H Barthel; J Schwarz; D Polster; A Wagner; O Sabri
Journal:  J Neural Transm (Vienna)       Date:  2006-02-06       Impact factor: 3.575

8.  Second consensus statement on the diagnosis of multiple system atrophy.

Authors:  S Gilman; G K Wenning; P A Low; D J Brooks; C J Mathias; J Q Trojanowski; N W Wood; C Colosimo; A Dürr; C J Fowler; H Kaufmann; T Klockgether; A Lees; W Poewe; N Quinn; T Revesz; D Robertson; P Sandroni; K Seppi; M Vidailhet
Journal:  Neurology       Date:  2008-08-26       Impact factor: 9.910

9.  Biomarkers to detect central dopamine deficiency and distinguish Parkinson disease from multiple system atrophy.

Authors:  David S Goldstein; Courtney Holmes; Oladi Bentho; Takuya Sato; Jeffrey Moak; Yehonatan Sharabi; Richard Imrich; Shielah Conant; Basil A Eldadah
Journal:  Parkinsonism Relat Disord       Date:  2008-03-05       Impact factor: 4.891

10.  Meta-analysis of the literature on diagnostic accuracy of SPECT in parkinsonian syndromes.

Authors:  Annemarie M M Vlaar; Marinus J P G van Kroonenburgh; Alfons G H Kessels; Wim E J Weber
Journal:  BMC Neurol       Date:  2007-09-01       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.